patent/TW-I760419-B

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I760419-B

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bf8ddd7435c69cd1b353b1292981d68
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
classificationIPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
filingDate	2018-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate	2022-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7786b4539e4361b370090504ecb8fc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38fa2b7e35132e780257dedc4ecc97f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6b3483fb5b1b6570c83dc8efb009313 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44f9a943d5c65d70d8229a5fe47460b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60c6e8c73299a774c207eddce7f29c48
publicationDate	2022-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	TW-I760419-B
titleOfInvention	Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
abstract	The present invention relates to a compound according to formula (I) or pharmaceutically acceptable salts, hydrates, or solvates thereof; wherein R 1 nis C 1 n-alkyl, R 2 nis C 1 n-alkyl, R 3 nis C 2 n-alkyl, R 4 nis hydrogen, R 5 nis hydrogen. The invention relates further to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to said compounds for use in the treatment autoimmune diseases and to intermediates for the preparation of said compounds.
priorityDate	2017-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011086053-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2518071-A1
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422062067 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID6612803 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID43568 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID6730163 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID43569 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID179897

Total number of triples: 35.